Study indicates Merck's Ervebo vaccine may provide cross-protection against non-Zaire ebolaviruses

New research suggests Merck's Ervebo vaccine, currently licensed for the Zaire ebolavirus, may offer efficacy against other ebolavirus species. The findings provide a potential pathway for expanded use in the Democratic Republic of the Congo, though clinical validation remains necessary to confirm cross-species protection.